Professor Rajpoot, Director of the Tissue Image Analytics (TIA) Centre at the University of Warwick, has been announced as the new GSK Chair of Computational Pathology at the University of Warwick.
Pathology images contain an immense amount of data which have long been used for diagnosis and prognosis in the practice of medicine. The advent of AI computer vision methods has transformed the practice of pathology leading to a new discipline of computational pathology. Combining the data in pathology slides with other sources of data (in what is termed multi-modal data fusion) has the potential to create the next generation of diagnostic tools for medicine, enabling the selection of appropriate medicines for a patient and predicting their disease outcomes.
Professor Nasir Rajpoot is one of the leading experts and has published extensively in the field and led the creation of unique datasets that have spurred innovation in other Universities and research organisations across the globe.
Professor Rajpoot commented: “I’m delighted to be taking up this position as the Chair and am very much looking forward to strengthening the Warwick-GSK relationship in the future. AI carries immense potential to revolutionise and personalise cancer care and drug development, and engagements like this are critical to realising that potential.”
“Computational pathology is one of the key innovations we are pioneering at GSK and we look forward to bringing these methods to the clinic to support the creation of innovative medicines. Supporting Nasir at Warwick is one of the ways we can help getting ahead of disease together,” said Kim Branson, SVP and Global Head of Artificial Intelligence and Machine Learning, GSK.
The new role shows a commitment by GSK to deepen an already existing partnership with Warwick, with Professor Rajpoot’s appointment being the latest in a series of investments in this field at the University.
Pictured above are (left to right): Professor Nasir Rajpoot, Dr Kim Branson (Senior Vice President and Global Head of AI and ML, GSK) and Dr Tony Wood (Chief Scientific Officer, GSK).
